Type of product: | Release of new product: other (technical documentation)Due to permanently increasing biosafety regulations, modern immunology has faced a problem concerning the demands of development of effective vaccines against small antigens, since using killed pathogenic cells or toxins are either already successfully utilized for producing effective vaccines or their use is limited due to biosafety concerns. At the same time recombinant technologies is not only capable of providing specific DNA or proteins possessing antigenic properties, but also are relatively safe. However, individual molecules possess low immunogenicity, and need to be coupled with stronger immunogenic substance providing adjuvant action.
In the recent years, there is a burst in papers describing different approaches and strategies towards creation of targeted nanoparticles for drug, gene delivery, as well as for bio-imaging. While the delivery systems based on nanotechnologies are currently well described, the adjuvant properties of the nanoparticles to be applied are poorly studied. The only two nano-sized vaccine adjuvants so far approved for human use, are MF59 and AS04, and they have been the only new adjuvants approved for human use over the last 70 years (Tagliabue, Rappuoli, 2008).
In this work, we studied potential adjuvant properties of polymeric nanoparticles (~75 nm in diameter) in two experimental models – “high” immunogenic model of rabbits immunized with soybean proteins (evolutionary distant proteins) and “low” immunogenic model of mice immunized with total calf histones (evolutionary close proteins). In both cases, nanoparticles had on their surface reactive epoxy groups which were utilized for conjugation of proteins - immunogenes. Freund adjuvant was applied as a positive control of immunogenicity. Our results demonstrated strong adjuvant |